Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Proxygen partnered with Germany-based Merck to jointly identify and develop molecular glue degraders for clinical research.
While tools to reverse age-related cellular dysfunction haven’t yet reached the masses, two research studies have emerged this week that hint at progress.
Bristol Myers Squibb announced Friday that it is acquiring San Diego-based Turning Point Therapeutics in a deal totaling about $4.1 billion.
June is starting off with a number of important dates for the FDA, including an advisory committee meeting to discuss COVID-19 vaccines in children as young as six months.
The FDA requested more data on effectiveness, particularly evidence that shows plasma arginine and metabolic reduction can predict clinical benefit in patients living with ARG1-D.
BioSpace spoke with Payton Nyquvest, co-founder and CEO of Numinus about changing perceptions around psychedelic-assisted psychotherapy and the company’s work in this space.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Centessa announced Thursday it is discontinuing the development of its lead asset, lixivaptan, for autosomal dominant polycystic kidney disease (ADPKD).
Bristol Myers Squibb’s Orencia and Johnson & Johnson’s Remicade improved survival rates for people hospitalized with COVID-19 according to a new report by the National Institutes of Health.
Tessera Therapeutics announced Thursday that ex-AbbVie executive Michael Severino, M.D. will take the helm of the young biotech.
With June just getting started, BMS and Sorrento are making new connections. Read on for announcements of these collaborations.
Monkeypox is not COVID-19, but both are viral diseases that are front-and-center in the world of public health and epidemiology. Here’s a look at the latest news on both outbreaks.